Evidence map›Paper›PMID 39596005›Full record

ArticleInternational journal of molecular sciences2024

Metformin Impairs Linsitinib Anti-Tumor Effect on Ovarian Cancer Cell Lines.

Diana Luísa Almeida-Nunes, João P N Silva, Mariana Nunes, Patrícia M A Silva, Ricardo Silvestre, Ricardo Jorge Dinis-Oliveira, Hassan Bousbaa, Sara Ricardo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Diana Luísa Almeida-NunesAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.ORCID 0000-0003-4270-7701
João P N SilvaUNIPRO-Oral Pathology and Rehabilitation Research Unit, Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal.ORCID 0000-0003-4455-4286
Mariana NunesDifferentiation and Cancer Group, Institute for Research and Innovation in Health (i3S) of the University of Porto, 4200-135 Porto, Portugal.ORCID 0000-0002-4733-5778
Patrícia M A SilvaAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.ORCID 0000-0002-0694-7321
Ricardo SilvestreLife and Health Sciences Research Institute (ICVS), School of Medicine from University of Minho, 4710-057 Braga, Portugal.
Ricardo Jorge Dinis-OliveiraAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.ORCID 0000-0001-7430-6297
Hassan BousbaaUNIPRO-Oral Pathology and Rehabilitation Research Unit, Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Politécnico e Universitário (CESPU), Rua Central de Gandra 1317, 4585-116 Gandra, Portugal.ORCID 0000-0002-4006-5779
Sara RicardoAssociate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.ORCID 0000-0003-4091-2226

Funding

Cooperativa de Ensino Superior Politécnico e Universitário AntiMitoSphere_APSFCT_IINFACTS_2021Cooperativa de Ensino Superior Politécnico e Universitário BD/CBAS/CESPU/01/2021Cooperativa de Ensino Superior Politécnico e Universitário Flav4Tumor-GI2-CESPU-2022Cooperativa de Ensino Superior Politécnico e Universitário ImmunoT4OC_GI2- CESPU-2023Cooperativa de Ensino Superior Politécnico e Universitário SGA4Cancer-GI2-CESPU-2022Cooperativa de Ensino Superior Politécnico e Universitário upPTXovcar-GI2-CESPU-2022Fundação para a Ciência e Tecnologia 10.54499/2020.00185.CEECIND/CP1600/CT0004Fundação para a Ciência e Tecnologia 2021.05081.BDFundação para a Ciência e Tecnologia DOI: 10.54499/2020.04720.BDFundação para a Ciência e Tecnologia DOI: 10.54499/LA/P/0050/2020Fundação para a Ciência e Tecnologia DOI: 10.54499/UIDB/50026/2020Fundação para a Ciência e Tecnologia DOI: 10.54499/UIDP/50026/2020
6 · The paper itself

Abstract

Ovarian cancer (OC) remains one of the leading causes of cancer-related mortality among women. Targeting the insulin-like growth factor 1 (IGF-1) signaling pathway has emerged as a promising therapeutic strategy. Linsitinib, an IGF-1 receptor (IGF-1R) inhibitor, has shown potential in disrupting this pathway. Additionally, metformin, commonly used in the treatment of type 2 diabetes, has been studied for its anti-cancer properties due to its ability to inhibit metabolic pathways that intersect with IGF-1 signaling, making it a candidate for combination therapy in cancer treatments. This study explores the anti-cancer effects of linsitinib and metformin on OVCAR3 cells by the suppression of the IGF-1 signaling pathway by siRNA-mediated

Indexed as

ApoptosisCell ProliferationImidazolesMetforminOvarian NeoplasmsAntineoplastic AgentsCell Line, TumorCell SurvivalDrug SynergismFemaleHumansInsulin-Like Growth Factor IPyrazinesReceptor, IGF Type 1Signal Transduction3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanolAntineoplastic AgentsImidazolesInsulin-Like Growth Factor IMetforminPyrazinesReceptor, IGF Type 1apoptosiscell viabilityIGF-1 signaling pathwaylinsitinibmetforminovarian cancer

Identifiers

PMID39596005
PMCPMC11594113

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.